MAP2K7 and melanoma: The combined use of a phosphoinositide-dependent kinase 1 (PDPK1) inhibitor (GSK2334470) and a MEK inhibitor (trametinib) suppressed NRAS-mutant xenograft growth and induced GSDME-associated pyroptosis in NRAS-mutant melanoma model mice [76].